No Detail Found!

METFORMIN MODULATES SERUM CA 19-9 AND ITS RELATED FACTORS MORE EFFECTIVELY THAN GLIBENCLAMIDE IN DIABETIC PATIENTS

Author(s)
Mohammad Waqas Khyber College of Dentistry,Peshawar, KP,Pakistan
Muhammad Idrees Department of Pathology, Khyber Medical College,Peshawar, KP,Pakistan
Saima Qayyum Department of Pathology, Khyber Medical College,Peshawar, KP,Pakistan
Muhammad Ihtesham Department of Pathology, Khyber Medical College,Peshawar, KP,Pakistan
Mohsin Shafi Department of Pathology, Khyber Medical College,Peshawar, KP,Pakistan
Inayat U Rahman Kabir Medical College, Gandhara University,Peshawar, KP,Pakistan
Abstract
Objective: CA 19-9 is a marker that shows the relapse of tumors. Raised CA 19-9 in diabetes mellitus cases and the effect of hypoglycemic agents on the marker prompted us to compare the effect of metformin and glibenclamide on CA 19-9 levels in patients with diabetes mellitus. Material & Methods: It is a randomized control trial (RCT). Normal control (group A1) included 40 staff members from KTH/ KMC. A total number of 79 patients with type 2 diabetes mellitus were randomized into two groups; group A2 (n=39) who took metformin (500 mg/day) and group A3 (n=40) received glibenclamide (2.5 mg/day). The study was conducted for 6 months and variables including fasting blood glucose, blood lipids, plasma sialic acid, HbA1-c, insulin and C-peptide, CA 19-9, and insulin resistance were measured initially and at week 10. Results: At the endpoint, there were reductions in FBG and HbA1C levels among metformin and glibenclamide groups compared to baseline (p<0.003, p<0.001, and p<0.05, p=0.05 respectively). The metformin group also showed a significant re duction in CA 19-9 level from baseline (p=0.05) and the same was the case for PSA (p<0.04) but the effect of glibenclamide on CA 19-9 was negligible and PSA slightly increased (deteriorated) from baseline. Between groups comparison at the endpoint showed a significantly high level of PSA in the glibenclamide group than in the metformin group (p=0.05). Insulin, HOMA-IR, and C-peptide levels improved in both groups from baseline. The favorable effects of metformin on blood lipids and body weight were more than glibenclamide. Correlation studies revealed a significantly positive correlation (p=0.05) of CA 19-9 with FBG, HbA1-c, PSA, insulin, and triglyceride levels in the metformin group, and FBG, HbA1-c, PSA, and total cholesterol in glibenclamide group. Conclusions: From these findings, we suggest greater beneficial effects of metformin on CA 19-9 and other related factors than glibenclamide.
Publication Details
Page(s) 212-215
DOI DOI not available
Published Journal: Journal of Medical Science, Volume: 30, Issue: 3, Year: 2022

Request the full text from PASTIC

Keywords
Diabetes mellitus, Diabetes mellitus, Metformin, Glibenclamide, CA 19-9
0

Citations

0

Downloads

66

Views